Phase I trial of capecitabine, oxaliplatin and irinotecan combination chemotherapy (XELOXIRI) for advanced gastric cancer
Not Applicable
- Conditions
- Advanced gastric cancer
- Registration Number
- JPRN-UMIN000022861
- Lead Sponsor
- Kyushu University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
Not provided
Exclusion Criteria
1) HER2 positive 2) UGT1A1 *6 or *28 homozygote or *6 and *28 heterozygote 3) Symptomatic brain metastasis 4) Infectious disease 5) Grade 2 or more diarrhea 6) Grade 2 or more peripheral sensory neuropathy 7) Massive pleural effusion, ascites, or cardiac effusion 8) Ileus 9) Defined interstitial pneumonia
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Dose limiting toxicity
- Secondary Outcome Measures
Name Time Method objective response rate disease control rate adverse event